Springer Nature
Browse
40164_2019_138_MOESM3_ESM.docx (36.3 kB)

MOESM3 of Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma

Download (36.3 kB)
journal contribution
posted on 2019-07-03, 05:00 authored by Ravi Potluri, Sandip Ranjan, Hitesh Bhandari, Helen Johnson, Andriy Moshyk, Srividya Kotapati
Additional file 3. Year-wise split of drug costs into pre- and post-progression periods, per patient.

Funding

Bristol-Myers Squibb

History

Usage metrics

    Experimental Hematology & Oncology

    Categories

    Keywords

    Advanced melanomaMelanomaNivolumabIpilimumabHealthcare cost comparisonCheckMate 067NCT01844505

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC